Understanding Voting Rights and Share Capital Structure at Nanobiotix
In accordance with Articles L.233-8 II of the French Commercial Code and the regulations set forth by the French Financial Markets Authority, companies like Nanobiotix are required to regularly disclose information about their voting rights and share capital. This disclosure serves to keep stakeholders informed about the number of shares available for voting, crucial for corporate decisions.
Recent Developments in Voting Rights
On September 30, Nanobiotix reported a total of 47,426,851 shares outstanding. These figures are pivotal as they outline the voting rights available to shareholders. Currently, there are 49,200,752 theoretical voting rights, which include all shares to which voting rights are attached, regardless of any that may have been suspended. On the other hand, the exercisable voting rights total 49,178,634, indicating the actual rights that can be exercised by shareholders at meetings.
Why Voting Rights Matter
Understanding the dynamics of voting rights is essential for shareholders, as it directly impacts their influence over corporate governance. In a world where shareholder activism is gaining ground, having a clear picture of voting rights allows investors to participate actively in shaping the strategies and policies of the company.
About Nanobiotix
Nanobiotix is a leading late-stage clinical biotechnology company headquartered in Paris. Founded in 2003, Nanobiotix is recognized for pioneering innovative, physics-based therapies that radically aim to transform treatment outcomes for patients, particularly in oncology. The firm is committed to exploring the vast potential of nanotechnology to enhance medical interventions.
Nano's Corporate Philosophy
The Company's mission is to expand the horizons of treatment possibilities by leveraging advanced nanotechnology. Nanobiotix holds more than 25 patents across three key platforms that target oncology, bioavailability, and disorders of the central nervous system. This commitment to innovation underpins their operations and research endeavors.
Recent Market Activity and Corporate Strategy
Since its listing on Euronext Paris in 2012 and later on the Nasdaq Global Select Market in December 2020, Nanobiotix has established itself as a key player in the biotech sector. The Company’s strategic focus involves enhancing its research capabilities and expanding its market reach. Continuous investment in technology and collaboration with key stakeholders positions Nanobiotix for future growth, aiming to positively impact the therapeutic landscape.
Contacting Nanobiotix
For inquiries, individuals can reach out to the Communications Department at Nanobiotix. Brandon Owens, the VP of Communications, can be contacted at +1 (617) 852-4835. Potential investors should connect with Craig West, SVP of Investor Relations, reachable at +1 (617) 583-0211. For further inquiries about media relations, Ulysse Communication’s Laurent Wormser is available at +33 (0)6 13 12 04 04. Global inquiries can be directed to LifeSci Advisors, specifically Kevin Gardner at +1 (617) 283-2856.
Frequently Asked Questions
What are voting rights at Nanobiotix?
Voting rights represent the number of shares that can be voted on by shareholders, influencing corporate decisions during shareholder meetings.
How many shares are currently outstanding for Nanobiotix?
As of September 30, 2024, Nanobiotix has reported 47,426,851 shares outstanding.
What is the significance of theoretical voting rights?
Theoretical voting rights include all shares with attached voting rights, even if some may be temporarily suspended, ensuring a full picture of potential influence.
How does Nanobiotix's corporate philosophy impact its operations?
Nanobiotix's philosophy emphasizes innovation and the use of advanced technologies to improve treatment outcomes, driving its research and development efforts.
Where can I find more information about Nanobiotix?
For detailed information, including their latest updates and corporate news, visit Nanobiotix's official website.
